+44-3308187254
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions
| Xiao-Wu Chen1, Wanqing Liu2 and Shu-Feng Zhou3* | |
| 1Department of General Surgery, The First People’s Hospital of Shunde, Southern Medical University, Shunde, Guangdong 528300, China | |
| 2Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, USA | |
| 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, USA | |
| Corresponding Author : | Shu-Feng Zhou, MD, PhD Associate Vice President for Global Medical Development Department of Pharmaceutical Sciences College of Pharmacy University of South Florida 12901, Bruce B Downs Blvd. Tampa, FL 33612, USA Tel: 813 974-6276 Fax: 813 905-9885 E-mail: szhou@health.usf.edu |
| Received November 08, 2012; Accepted November 27, 2012; Published November 30, 2012 | |
| Citation: Chen XW, Liu W, Zhou SF (2012) Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions. Clinic Pharmacol Biopharm. 1:104. doi:10.4172/2167-065X.1000104 | |
| Copyright: © 2012 Chen XW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Adverse drug reactions (ADRs) are one of the major causes of patient morbidity and mortality. Pharmacogenomics is the study of how individual response to drugs is affected by genetic mutations at the genome level. There is clinical evidence that polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets (e.g. receptors & enzymes) can lead to the occurrence of ADRs. In addition, mutations of certain genes can precipitate ADRs. Over the past years, genome-wide association studies (GWAS) have identified a number of common and rare variants that are associated with increased risk of ADRs. As affordable and reliable genetic testing tools become available to physicians, pharmacogenomics looks promising to facilitate individualization of drug therapy and as a result, this will maximize the therapeutic efficacy of drugs in patients while minimizing the occurrence of ADRs.
